和誉-B(02256)：和誉医药于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合 EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果

智通财经2025-12-08

智通财经APP讯，和誉-B(02256)发布公告，2025年12月8日，上海和誉生物医药科技有限公司(和誉医药)宣布，其在 2025年欧洲肿瘤内科学会亚洲年会(ESMO Asia 2025)公布其在研口服小分子 PD-L1抑制剂ABSK043联合上海艾力斯医药科技股份有限公司(艾力斯)第三代EGFR-TKI伏美替尼治疗非小细胞肺癌(NSCLC)的II期临床研究(ABSK043- 202)剂量递增...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2589801094?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-08 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589801094","market":"hk","top_or_hot":-1,"title":"和誉-B(02256)：和誉医药于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合 EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果","media":"智通财经","content":"<div>\n<p>智通财经APP讯，和誉-B(02256)发布公告，2025年12月8日，上海和誉生物医药科技有限公司(和誉医药)宣布，其在 2025年欧洲肿瘤内科学会亚洲年会(ESMO Asia 2025)公布其在研口服小分子 PD-L1抑制剂ABSK043联合上海艾力斯医药科技股份有限公司(艾力斯)第三代EGFR-TKI伏美替尼治疗非小细胞肺癌(NSCLC)的II期临床研究(ABSK043- 202)剂量递增...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1378554.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和誉-B(02256)：和誉医药于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合 EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和誉-B(02256)：和誉医药于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合 EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 08:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1378554.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和誉-B(02256)发布公告，2025年12月8日，上海和誉生物医药科技有限公司(和誉医药)宣布，其在 2025年欧洲肿瘤内科学会亚洲年会(ESMO Asia 2025)公布其在研口服小分子 PD-L1抑制剂ABSK043联合上海艾力斯医药科技股份有限公司(艾力斯)第三代EGFR-TKI伏美替尼治疗非小细胞肺癌(NSCLC)的II期临床研究(ABSK043- 202)剂量递增...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1378554.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BPRC5H50.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1378554.html","article_id":"2589801094","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589801094","pubTimestamp":1765152368,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"数据显示，ABSK043与伏美替尼的“靶免联合”方案展现出良好的安全性和耐受性。研究结果显示，ABSK043联合伏美替尼表现出可控的安全性和良好的耐受性。剂量递增阶段的研究结果表明，ABSK043联合伏美替尼不仅安全性可控、耐受性良好，还展现出令人鼓舞的初步抗肿瘤活性。上述积极结果为正在开展的剂量扩展阶段奠定了基础，该阶段将评估ABSK043联合伏美替尼作为一线疗法，用于治疗初治的EGFR突变、PD-L1阳性的NSCLC患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","09939":"开拓药业-B","BK1574":"生物医药B类股","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","02256":"和誉-B","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","PD":"PagerDuty, Inc.","BK4023":"应用软件","BK1161":"生物科技","BK1515":"抗疫概念","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC"},"translate_title":"Harmony-B (02256): Harmony Pharma announced the preliminary phase II clinical results of oral PD-L1 inhibitor ABSK043 combined with EGFR inhibitor fumetinib in the treatment of NSCLC at ESMO Asia 2025","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"PD":1.5,"02256":1.5,"09939":1.5},"content_text":"智通财经APP讯，和誉-B(02256)发布公告，2025年12月8日，上海和誉生物医药科技有限公司(和誉医药)宣布，其在 2025年欧洲肿瘤内科学会亚洲年会(ESMO Asia 2025)公布其在研口服小分子 PD-L1抑制剂ABSK043联合上海艾力斯医药科技股份有限公司(艾力斯)第三代EGFR-TKI伏美替尼治疗非小细胞肺癌(NSCLC)的II期临床研究(ABSK043- 202)剂量递增阶段的积极结果。数据显示，ABSK043与伏美替尼的“靶免联合”方案展现出良好的安全性和耐受性。监管部门基于该方案良好的安全性，同意将其拓展至用于EGFR突变且PD-L1阳性NSCLC患者的一线治疗研究。表皮生长因子受体(EGFR)突变是NSCLC中最常见的致癌驱动基因突变。尽管第三代EGFR-TKIs已成为EGFR突变晚期NSCLC的一线标准治疗方案，但研究表明，与PD-L1低表达或阴性患者相比，EGFR突变合并PD-L1高表达的患者从 EGFR-TKIs的治疗中获益较少。此外，虽然免疫治疗已在多个癌种中表现出卓越疗效，但PD-1/PD-L1抗体与EGFR-TKI的联合方案因严重毒副反应而受到限制，使得该类患者人群的临床需求仍未得到满足。在本届ESMO Asia 2025上，上海交通大学医学院附属上海胸科医院陆舜教授以壁报形式展示了正在开展的II期研究(ABSK043-202)剂量递增阶段的积极结果。在剂量递增阶段，共纳入21例EGFR突变且PD-L1阳性的经治晚期NSCLC患者，其中17例患者曾接受过第三代EGFR-TKIs治疗。研究结果显示，ABSK043联合伏美替尼表现出可控的安全性和良好的耐受性。截至数据分析时，未观察到剂量限制性毒性(DLTs)和间质性肺炎(ILD)，最常见的治疗相关不良反应(TEAEs)为1-2级，未观察到4级或5级TEAE。该联用方案还展现出积极的抗肿瘤活性。依据RECIST v1.1标准评估的疾病控制率(DCR)达到71%，共有14例患者实现靶病灶缩小。在达到部分缓解(PR)的5例患者中，有4例曾接受过第三代EGFR-TKI的治疗。截至数据分析时，中位缓解持续时间(DOR)尚未达到。剂量递增阶段的研究结果表明，ABSK043联合伏美替尼不仅安全性可控、耐受性良好，还展现出令人鼓舞的初步抗肿瘤活性。这种口服+口服的“靶免联合”创新治疗策略有望克服以往EGFR-TKIs与免疫治疗抗体联用所面临的毒性挑战。上述积极结果为正在开展的剂量扩展阶段奠定了基础，该阶段将评估ABSK043联合伏美替尼作为一线疗法，用于治疗初治的EGFR突变、PD-L1阳性的NSCLC患者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589801094","isCrawlerRequest":true}